CA-4948-104: A Ph1 Study of Emavusertib in AML CR MRD+ Patients Currently Receiving Azacitidine and Venetoclax

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-505828-58-00

Acronym

CA-4948-104

Enrollment

Registered

2023-10-20

Start date

2023-12-05

Completion date

Unknown

Last updated

2025-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myeloid Leukemia

None listed

Sex/Gender

All

Age

18 Years to No maximum

Germany, Italy, Spain

None listed

Source: EU CTIS · Data processed: Feb 8, 2026